AbbVie Q2 Earnings: Revenue Up 10%, Raises Guidance Despite Apogee Dilution
ABBV sits 33% above its 52-week low of $187.62.
Summary
AbbVie reported Q2 2026 revenue of $16.99 billion, up 10.2% year-over-year, with adjusted EPS of $3.65. The company updated full-year adjusted EPS guidance to $13.87-$14.07, including $0.14 dilution from the Apogee acquisition expected to close in Q3.
Key Events · Earnings and Guidance · ABBV
-
Q2 Revenue and Earnings Beat
Net revenues rose 10.2% to $16.99 billion; adjusted diluted EPS of $3.65 increased 22.9% year-over-year, driven by immunology and neuroscience growth.
-
Immunology Portfolio Strength
Global immunology revenues reached $8.79 billion, up 15.1%, with Skyrizi at $5.51 billion (+24.4%) and Rinvoq at $2.53 billion (+24.5%), more than offsetting Humira's decline.
-
Full-Year Guidance Updated
2026 adjusted diluted EPS guidance narrowed to $13.87-$14.07, reflecting $0.14 dilution from the Apogee acquisition and $0.10 of operational overperformance.
-
Apogee Acquisition Progress
The $10.9 billion acquisition of Apogee Therapeutics is on track to close in Q3 2026, adding late-stage immunology assets with mega-blockbuster potential.
Analysis · ABBV · Life Sciences
AbbVie delivered a strong second quarter with revenue growing 10.2% to $16.99 billion, driven by its immunology and neuroscience franchises. Adjusted EPS of $3.65 beat expectations, and the company raised the midpoint of its full-year adjusted EPS guidance to $13.97, absorbing $0.14 of dilution from the pending Apogee acquisition. The results demonstrate robust commercial execution and pipeline momentum, offsetting Humira erosion and positioning the company for sustained growth.
At the time of this filing, ABBV was trading at $250.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $454.8B. The 52-week trading range was $187.62 to $267.47. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.